New cheaper insulin on the horizon? biosimilar I004 tested against NovoLog
NCT ID NCT07560150
First seen May 02, 2026 · Last updated Jun 23, 2026 · Updated 9 times
Summary
This study compares a new rapid-acting insulin called I004 to the approved insulin NovoLog in 60 healthy adults. Researchers want to see if the two insulins are similar in how they work in the body. If they are, I004 could become a more affordable option for managing diabetes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACODYNAMICS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amphastar Study Site
RECRUITINGChula Vista, California, 91911, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Insulin aspart (a rapid-acting insulin analogue)
What this could lead to
If successful, this could lead to a more affordable biosimilar insulin for people with diabetes, helping to lower treatment costs.
What could go wrong
This is an early-stage study in healthy volunteers, not people with diabetes. It only measures short-term effects, so it may not predict real-world outcomes or long-term safety.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.